Experimental study demonstrates enhanced microhardness and controlled zinc ion release in modified beta-titanium alloy, indicating potential for improved biomedical implants.
Ti-35Nb-2Ta-3Zr (TNTZ) β-titanium alloy is attractive for biomedical applications because of its relatively low elastic modulus and composition based on nominally non-cytotoxic alloying elements; however, its surface hardness and intrinsic bioactivity remain limited. In this study, Zn nanoparticles were incorporated into the near-surface region of TNTZ by friction stir processing (FSP), followed by compression plasma flow (CPF) treatment in nitrogen. Cross-sectional scanning electron microscopy and energy-dispersive X-ray spectroscopy, X-ray diffraction, microhardness testing, and inductively coupled plasma mass spectrometry after 60 days of immersion in simulated body fluid were used to characterize the modified layers. CPF treatment produced a distinct surface-modified layer approximately 10–15 μm thick, increased the Zn signal within the upper approximately 11 μm, and generated diffraction peaks assigned to Ti2N. The fitted β-phase lattice parameter decreased with nominal X-ray penetration depth, and tensile residual stresses were calculated for all CPF-treated conditions. Sample 1 exhibited the highest microhardness at the lowest applied load. After 60 days of immersion, the mean Zn concentration was 261.87 ± 0.0031 μg/L for FSP and 102.41 ± 0.0063 μg/L for FSP + CPF, corresponding to an approximately 60.9% lower mean cumulative Zn concentration after CPF treatment. Electrochemical, tribological, and biological testing is still required to establish corrosion, wear, and biological performance.
No takes yet. Share an insight, caveat, or question.
Pavukova et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: